Cetera Investment Advisers Has $10.90 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

Cetera Investment Advisers cut its position in DexCom, Inc. (NASDAQ:DXCM) by 10.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 96,151 shares of the medical device company’s stock after selling 10,730 shares during the period. Cetera Investment Advisers’ holdings in DexCom were worth $10,902,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of DXCM. Bank of New Hampshire bought a new position in DexCom during the first quarter worth about $1,508,000. Waters Parkerson & CO. LLC grew its position in DexCom by 4.2% in the 2nd quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock valued at $30,912,000 after purchasing an additional 10,892 shares during the period. Legal & General Group Plc boosted its holdings in DexCom by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after acquiring an additional 49,076 shares during the last quarter. Los Angeles Capital Management LLC boosted its holdings in shares of DexCom by 62.5% in the 1st quarter. Los Angeles Capital Management LLC now owns 357,033 shares of the medical device company’s stock worth $49,520,000 after buying an additional 137,336 shares during the last quarter. Finally, Cullen Investment Group LTD. bought a new stake in DexCom in the 1st quarter valued at about $1,349,000. 97.75% of the stock is owned by institutional investors.

Insider Buying and Selling at DexCom

In other news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other DexCom news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,824 shares of company stock valued at $126,390. 0.30% of the stock is currently owned by company insiders.

DexCom Stock Up 3.7 %

Shares of NASDAQ DXCM opened at $68.11 on Friday. The firm has a market cap of $27.09 billion, a PE ratio of 43.94, a P/E/G ratio of 2.16 and a beta of 1.18. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company’s fifty day simple moving average is $70.19 and its 200 day simple moving average is $104.95. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.34 earnings per share. As a group, sell-side analysts forecast that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on DXCM. Canaccord Genuity Group restated a “buy” rating and set a $145.00 price target on shares of DexCom in a research note on Tuesday, July 23rd. Morgan Stanley dropped their price target on DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a research report on Friday, July 26th. Robert W. Baird increased their price target on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. JPMorgan Chase & Co. lowered DexCom from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $145.00 to $75.00 in a report on Friday, July 26th. Finally, Stifel Nicolaus raised their target price on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, August 23rd. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $112.25.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.